Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0111969" target="_blank" >RIV/00843989:_____/25:E0111969 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/25:A2603DMI
Result on the web
<a href="https://doi.org/10.1016/S2352-3026(25)00117-6" target="_blank" >https://doi.org/10.1016/S2352-3026(25)00117-6</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S2352-3026(25)00117-6" target="_blank" >10.1016/S2352-3026(25)00117-6</a>

Result language
angličtina
Original language name
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network
Original language description
Novel T-cell immunotherapies (chimeric antigen receptor [CAR] T cells and T-cell redirecting bispecific antibodies) are changing the treatment landscape of relapsed or refractory multiple myeloma. In this Review, the European Myeloma Network provides recommendations to optimise both safety and efficacy of T-cell immunotherapy. In patients who are eligible for both CAR T-cell therapy and bispecific antibodies, we recommend using CAR T-cell therapy first due to the high response rate and durable progression-free survival, accompanied by improved quality of life. Furthermore, previous bispecific antibody treatment has a negative effect on the efficacy of CAR T-cell therapy, and there is emerging evidence that suggests that relapse after B-cell maturation antigen-directed CAR T-cell therapy can be effectively managed with bispecific antibodies. Timely referral and planning are crucial before initiating T-cell immunotherapy to optimise treatment selection, conduct adequate diagnostic tests (eg, excluding latent infections), and identify modifiable risk factors to improve clinical outcomes. Supportive care is crucial in all patients receiving T-cell immunotherapy to prevent non-relapse mortality.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)